VolitionRx Receives Acceptance of Compliance Plan from NYSE American

VolitionRx announced that on April 22, the NYSE American accepted the company's plan of compliance for continued listing on the exchange. On February 6, the company received a notice from the NYSE American stating that the company is not in compliance with the NYSE American continued listing standards requiring a company to have stockholders' equity of at least $2.0M if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, requiring a company to have stockholders' equity of at least $4.0M if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, and requiring a company to have stockholders' equity at least $6.0M if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The company was required to submit a plan to the NYSE American by March 8 advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. The company submitted a plan prior to the deadline. On April 22, the company received a notification from the NYSE American that the company's plan to regain compliance with the NYSE American's listing standards was accepted and granting the Company until August 6, 2027, to regain compliance with the continued listing standards. If the company does not regain compliance with the NYSE American listing standards by August 6, 2027, or if the company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings. The letter has no immediate impact on the listing of the company's shares of common stock and does not affect the company's ongoing business operations or its reporting requirements with the SEC.